Deborah Cho

Hogan Lovells

Contact
View Bio
RSS

Latest Posts › Abbreviated New Drug Application (ANDA)

Share:

SCOTUS won’t hear Teva v. GSK: Where does that leave us on FDA labeling carve-outs?

The Supreme Court of the United States has denied certiorari in the Teva v. GSK “skinny labeling” case, leaving intact the Federal Circuit’s August 2021 decision, which we summarized online here. In the article below, we...more

6/1/2023  /  Abbreviated New Drug Application (ANDA) , Denial of Certiorari , Food and Drug Administration (FDA) , Life Sciences , Orange Book , Pharmaceutical Industry , Pharmaceutical Patents , SCOTUS
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide